Here, we showed that CCL2/HGF co-treatment increased cell growth, survival, and invasion in DCIS.com and HCC1937 breast cancer cells over CCL2 or HGF treatment alone. The gene discussed is CCL2; the disease is ductal breast carcinoma in situ.